ClinicalTrials.gg
CompletedNCT07677163Updated Oct 9, 2026

A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007)

A Phase 1 interventional study of MK-1403 formulation (FM) 1 + additive and MK-1403 FM2 + additive in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

How we know

Updated Oct 9, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this trial is to learn about a trial medicine called MK-1403. Researchers designed MK-1403 to treat a type of heart and blood vessel disease called atherosclerotic cardiovascular disease (ASCVD).

Before giving a trial medicine to people with a health condition, researchers first do clinical trials in healthy people. This trial will help researchers learn about the safety of MK-1403 and if participants tolerate it. Tolerate means participants receive the trial medicine and they do not need to stop taking it due to health problems. The trial will also measure what happens to MK 1403 in a healthy person's body over time.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is in good health
  • Has a (BMI) ≥ 18 and ≤ 32 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Has history of cancer ()
  • Has a history of significant multiple and/or severe allergies
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    MK-1403 formulation (FM) 1 + additive, Fed

    MK-1403 FM 1 + additive tablet administered once orally at study dose after a high-fat meal.

    Drug: MK-1403 formulation (FM) 1 + additive

  • Experimental
    MK-1403 FM1 + additive, Fasted

    MK-1403 FM1 + additive tablet administered once orally at study dose in a fasted state.

    Drug: MK-1403 formulation (FM) 1 + additive

  • Experimental
    MK-1403 FM2 + additive, Fed

    MK-1403 FM2 tablet + additive administered once orally at study dose after a high-fat meal.

    Drug: MK-1403 FM2 + additive

Interventions

  • DrugMK-1403 formulation (FM) 1 + additive

    Oral tablet

  • DrugMK-1403 FM2 + additive

    Oral tablet

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 4 weeks

  2. Number of Participants Who Discontinue the Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 2 weeks

  3. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-inf) of MK-1403

    Blood samples will be collected to determine the AUC0-inf of MK-1403 in plasma.

    Time frame: Predose and at designated timepoints (up to 72 hours postdose)

  4. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-last) of MK-1403

    Blood samples will be collected to determine the AUC0-last of MK-1403 in plasma.

    Time frame: Predose and at designated timepoints (up to 72 hours postdose)

  5. Maximum Plasma Concentration (Cmax) of MK-1403

    Blood samples will be collected to determine the Cmax of MK-1403 in plasma.

    Time frame: Predose and at designated timepoints (up to 72 hours postdose)

07

Study locations

1 site
  • QPS-MRA, LLC ( Site 0001)
    South Miami, Florida 33143, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2026 to primary completion in Oct 2026, 1 month.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Sep 2026 → Oct 2026 and completion Sep 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jun 30, 2026
StartActual
Aug 14, 2026
Primary completionActual
Oct 5, 2026was Sep 2026
CompletionActual
Oct 5, 2026was Sep 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 9, 2026
Primary completion
Sep 22, 2026→Oct 5, 2026 (actual)
Oct 9, 2026
Study completion
Sep 22, 2026→Oct 5, 2026 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Active, not recruiting→Completed
    Primary completion Sep 22, 2026→Oct 5, 2026 (now actual)
    Study completion Sep 22, 2026→Oct 5, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07677163
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
Aug 14, 2026
Primary completion
Oct 5, 2026
Completion
Oct 5, 2026
Last update
Oct 9, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion